楼主: bigfoot0517
2354 3

[外行报告] 汇丰银行--亚洲医疗产业研究报告2008年7月 [推广有奖]

  • 1关注
  • 21粉丝

学术权威

21%

还不是VIP/贵宾

-

威望
6
论坛币
12493617 个
通用积分
2.6112
学术水平
391 点
热心指数
369 点
信用等级
405 点
经验
28609 点
帖子
2147
精华
2
在线时间
242 小时
注册时间
2006-11-15
最后登录
2019-1-31

相似文件 换一批

+2 论坛币
k人 参与回答

经管之家送您一份

应届毕业生专属福利!

求职就业群
赵安豆老师微信:zhaoandou666

经管之家联合CDA

送您一个全额奖学金名额~ !

感谢您参与论坛问题回答

经管之家送您两个论坛币!

+2 论坛币

Our first ever Asia regional healthcare study concludes that stocks in the sector offer
both high growth and defensiveness – attractive qualities in current high volatility
markets. This view is echoed by our regional equity strategy team, which sees the
sector as a safe haven.
Growth in the sector is driven by strong structural domestic demand and
supplemented by rising exports. We prefer China and Korea, with a stronger preference
for China, given a slower growth rate and full valuations in India.
In this highly fragmented market, we look for strength in brand, marketing
& distribution and product quality. Our top picks are United Labs and Simcere in China,
Hanmi Pharma and Green Cross in Korea, and Dr. Reddy’s in India.

目录

Executive summary 1
China stock summary 8
Korea stock summary 11
India stock summary 15
Regional context 18
Industry overview 26
Country strategy and drivers 36
China strategy and drivers 37
Korea strategy and drivers 41
India strategy and drivers 48
Company overview: China 51
Golden Meditech (8180) 52
Mindray Medical Int’l (MR) 58
Mingyuan Medicare (233) 64
Shandong Weigao (8199) 69
Simcere Pharmaceutical (SCR) 75
United Laboratories International (3933) 81
WuXi PharmaTech (WX) 86
Company overview: Korea 93
Bukwang Pharma 94
Chong Kun Dang 102
Choongwae Pharma 110
Daewoong Pharma 119
Dong-A Pharma 128
Green Cross 138
Hanmi Pharma 145
LG Life Sciences 155
Three Seven 165
Yuhan Corp 171
Company overview: India 181
Apollo Hospitals 182
Biocon 187
Cipla 193
Dr. Reddy’s Labs 200
Ranbaxy 206
Sun Pharmaceuticals 212
Wockhardt 220
Appendix: Regulations 226
China regulations 227
Korea regulations 230
India regulations 237
Disclosure appendix 241
Disclaimer 244


[/UseMoney]

[UseMoney=500]

229753.pdf (2.06 MB, 需要: 500 个论坛币)


[此贴子已经被squarekiss于2008-7-23 8:57:06编辑过]

二维码

扫码加我 拉你入群

请注明:姓名-公司-职位

以便审核进群资格,未注明则拒绝

关键词:产业研究报告 研究报告 汇丰银行 产业研究 distribution 研究报告 亚洲 汇丰银行 医疗

沙发
wangdadu 发表于 2008-10-7 20:50:00 |只看作者 |坛友微信交流群
这么贵

使用道具

藤椅
bruce026 发表于 2009-9-10 11:37:49 |只看作者 |坛友微信交流群
太贵了吧

使用道具

板凳
horkyin 发表于 2009-12-3 15:22:24 |只看作者 |坛友微信交流群
既然拿出来分享,就不要卖这么贵吧

使用道具

您需要登录后才可以回帖 登录 | 我要注册

本版微信群
加JingGuanBbs
拉您进交流群

京ICP备16021002-2号 京B2-20170662号 京公网安备 11010802022788号 论坛法律顾问:王进律师 知识产权保护声明   免责及隐私声明

GMT+8, 2024-5-16 02:55